| Code | CSB-RA004936MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to DFI-105, targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a critical costimulatory molecule expressed on antigen-presenting cells, B lymphocytes, and various non-immune cells. It plays a pivotal role in adaptive immunity by regulating B cell activation, immunoglobulin class switching, and germinal center formation through interaction with its ligand CD40L. CD40 signaling is implicated in numerous pathological conditions, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as in cancer immunity where it can promote both tumor rejection and progression depending on context.
DFI-105 represents a therapeutic antibody designed to modulate CD40 signaling pathways. This biosimilar provides researchers with a valuable tool for investigating CD40-mediated immune responses, studying B cell biology, exploring immunomodulatory mechanisms in autoimmune disorders, and evaluating potential immunotherapeutic strategies in oncology research. The antibody enables detailed characterization of CD40 function in various experimental models and disease contexts.
There are currently no reviews for this product.